Crossmark Global Holdings Inc. Sells 344 Shares of Insulet Co. (NASDAQ:PODD)

Crossmark Global Holdings Inc. reduced its position in Insulet Co. (NASDAQ:PODD) by 9.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,133 shares of the medical instruments supplier’s stock after selling 344 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Insulet were worth $730,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. QRG Capital Management Inc. purchased a new stake in Insulet during the third quarter worth $297,000. Diversified Trust Co boosted its position in Insulet by 90.9% during the second quarter. Diversified Trust Co now owns 9,130 shares of the medical instruments supplier’s stock valued at $1,842,000 after purchasing an additional 4,348 shares in the last quarter. Natixis purchased a new position in Insulet in the first quarter valued at about $3,610,000. Intech Investment Management LLC raised its holdings in Insulet by 113.8% in the first quarter. Intech Investment Management LLC now owns 6,649 shares of the medical instruments supplier’s stock worth $1,140,000 after purchasing an additional 3,539 shares in the last quarter. Finally, Seven Eight Capital LP purchased a new stake in shares of Insulet during the first quarter valued at about $1,418,000.

Insulet Price Performance

Shares of NASDAQ PODD opened at $260.12 on Friday. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The firm’s 50 day simple moving average is $237.77 and its 200-day simple moving average is $207.47. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $279.40. The stock has a market capitalization of $18.25 billion, a price-to-earnings ratio of 44.54, a PEG ratio of 4.11 and a beta of 1.22.

Analysts Set New Price Targets

PODD has been the subject of several recent analyst reports. Citigroup boosted their price objective on shares of Insulet from $250.00 to $275.00 and gave the stock a “buy” rating in a research note on Tuesday, October 1st. Sanford C. Bernstein began coverage on Insulet in a report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price objective for the company. Raymond James boosted their target price on Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a research note on Monday, October 14th. BTIG Research increased their price target on Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Finally, Barclays boosted their price target on Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $253.27.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.